Mitapivat and Dordaviprone: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Mitapivat
Dordaviprone
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced dordaviprone exposure and reduced efficacy of dordaviprone
Interaction Deep Dive
Avoid coadministration of dordaviprone with a strong or moderate CYP3A4 inducer as it may reduce dordaviprone exposure, which may reduce the anti-tumor activity of dordaviprone. In drug interaction studies, dordaviprone Cmax is predicted to decrease by 68% and AUC by 83% following concomitant administration of rifAMPin (strong CYP3A4 inducer) and dordaviprone Cmax is predicted to decrease by 44% and AUC by 65% following concomitant administration of efavirenz (moderate CYP3A4 inducer)1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of dordaviprone
Literature reports
1 report — tap to read
a) In drug interaction studies, dordaviprone Cmax is predicted to decrease by 68% and AUC by 83% following concomitant administration of rifAMPin (strong CYP3A4 inducer) and dordaviprone Cmax is predicted to decrease by 44% and AUC by 65% following concomitant administration of efavirenz (moderate CYP3A4 inducer) 1.
Common questions
Can I take Mitapivat and Dordaviprone together?
Reduced dordaviprone exposure and reduced efficacy of dordaviprone Always confirm with your pharmacist or prescriber before making any change.
How serious is the Mitapivat and Dordaviprone interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Mitapivat or Dordaviprone need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: MODEYSO(TM) oral capsules, dordaviprone oral capsules. Jazz Pharmaceuticals, Inc. (per manufacturer), Palo Alto, CA, 2025. DailyMed
Keep reading about Mitapivat
Keep reading about Dordaviprone
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist